Cytosorbents outlines 2025 growth strategy with $1B market potential for DrugSorb-ATR
Cytosorbents Corporation (CTSO) reports 25% Q4 revenue growth, strong margins, and updates on FDA-reviewed DrugSorb-ATR launch.
Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsAdanna Alexander – IRPhillip Chan - ...
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Homestreet, Inc.
If you are a stockholder of HomeStreet, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: . You may also contact Shane Rowley, Esq. at ...